The Kenya Health Policy 2014-2030 aims at attaining the highest possible standard of health in a manner responsive to the health needs of our population. One of the major policy directions towards realizing the intentions of this policy is to halt and reverse the
rising burden of non-communicable d...iseases.
more
Meeting Report 27-29 October 2020
The overall goal of the meeting was to discuss recent changes in treatment regimens and diagnostics for drug-resistant TB and to determine how these impact on the definition of XDR-TB, with a view to revising this definition. The pre-existing definition of XDR-TB w...as formulated in 2006 at a meeting of the Global Taskforce on XDR-TB, convened by WHO, and has been in use for clinical and surveillance purposes, since this time.
more
n October 2019, WHO convened the first meeting of the Buruli ulcer laboratory network (BU-LABNET) in Yaoundé, Cameroon, bringing together 11 laboratories from nine countries at the Pasteur Centre of Cameroon (CPC), the network’s Coordinating Centre. The network was formally established at th...is meeting (1) and its members were those present. The objective of BU LABNET is to improve diagnosis of Buruli ulcer based on polymerase chain reaction (PCR) using standardized testing protocols, involving external quality assurance programmes and sharing knowledge among member laboratories.
more
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
The aim of the meeting was to broaden the network’s initiatives. Preliminary work involved integrating laboratory testing for skin NTDs other than Buruli ulcer, such as cutaneous leishmaniasis, mycetoma, leprosy and yaws, while extending the network’s reach to encompass additional laboratories.
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
Esta publicación presenta la Agenda para las Américas sobre salud, medioambiente y cambio climático 2021-2030. Esta agenda es un llamamiento al sector de la salud para que lidere la labor a fin de abordar los determinantes ambientales de la salud en la Región de las Américas. La Organización P...anamericana de la Salud (OPS) colaborará con sus Estados Miembros para alcanzar el propósito y el objetivo de esta agenda de promover el bienestar de todos a todas las edades, utilizando un enfoque sostenible y equitativo en el que se otorgue prioridad a la reducción de las inequidades en la salud. La agenda se ha elaborado bajo la égida de la Estrategia mundial de la OMS sobre salud, medio ambiente y cambio climático, y se basa en los compromisos establecidos en la Agenda de Salud Sostenible para las Américas 2018-2030 y el Plan Estratégico de la OPS 2020-2025. La agenda se elaboró en consulta con el grupo técnico asesor y mediante un proceso de toma de decisiones basado en el consenso con los Estados Miembros durante el período 2019-2020. Con la finalidad de alcanzar el Objetivo de Desarrollo Sostenible 3, la agenda se centra en: mejorar el desempeño de los programas e instituciones de salud pública ambiental; fomentar sistemas de salud sostenibles y resilientes desde el punto de vista medioambiental; y promover ciudades y comunidades saludables y resilientes desde el punto de vista medioambiental. Su aplicación será específica para cada contexto y se basará en las necesidades y realidades de los diversos países. Beneficiará a los países y territorios al promover prácticas de buena gobernanza, fortalecer el liderazgo y la coordinación en el sector de la salud, fomentar la acción intersectorial, centrarse en la prevención primaria, y mejorar la evidencia disponible y la comunicación. Facilitará el acceso a los recursos humanos, técnicos y financieros necesarios para abordar los determinantes ambientales de la salud y garantizará que la Región se involucre plenamente en los procesos y acuerdos mundiales sobre salud, medioambiente y cambio climático.
more
This document provides a decision-making framework for implementation of mass treatment interventions, active case-finding campaigns and population-based surveys for neglected tropical diseases in the context of the COVID-19 pandemic. A two-step approach is proposed: a risk–benefit assessment, to ...decide if the planned activity should proceed; and an examination of a list of precautionary measures that should be applied with the aim of decreasing the risk of transmission of COVID-19 associated with the activity, and strengthening the capacity of the health system to manage any residual risk. This guidance note is intended to health authorities, NTD programme managers and their supporting partners.
more
Severe acute respiratory infections treatment centre: practical manual to set up and manage a SARI treatment centre and a SARI screening facility in health care facilities
Guidance statement
Recommendations on contraceptive methods used by
women at high risk of HIV